Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the
“Company”), a global, integrated orthopedic and regenerative
medicines company specializing in therapeutics based on its
proprietary hyaluronic acid (“HA”) technology, today announced that
Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer
of Keratin Biosciences, Inc., has been appointed as a new
independent member of the Company’s Board of Directors with a term
continuing through the Company’s 2019 Annual Meeting of
Stockholders. With Dr. Blanchard’s appointment, the Board of
Directors has been expanded to seven directors.
“With more than 30 years of leadership and board experience in
medical devices and biotechnology, Cheryl is an outstanding
addition to Anika’s Board,” said Joseph L. Bower, Chairman of the
Board. “We are committed to strong corporate governance. We
continue to actively evaluate the composition of our Board to
ensure we have the right mix of expertise, independence, and
experience to best position Anika for the future.”
“Cheryl has an impressive track record of delivering strong
business results, and I am pleased she is joining Anika’s Board,”
said Joseph G. Darling, President and CEO of Anika. “As we undergo
a shift from palliative care to regenerative medicine, we could not
imagine someone better qualified than Cheryl to help guide us
through our next phase. As President and CEO of a drug delivery and
regenerative medicine company, she understands the path forward and
brings to the table considerable experience in corporate strategy,
R&D, commercialization, strategic partnerships, regulatory,
clinical and quality, operations, manufacturing, marketing, and
fundraising. We welcome her insights as we develop and implement
our five-year strategic plan to deliver and sustain double-digit
revenue growth beginning in 2019 and beyond.”
“This is an exciting time to join the Anika Board,” said Dr.
Blanchard. “I have followed Anika’s growth through the years and
have a deep appreciation for the Company’s world-class talent,
versatile and proprietary technology platform, and diverse
commercial portfolio with an exciting pipeline. I look forward to
working closely with the Anika team to effect a transformation that
continues to deliver solutions to help patients heal naturally and
faster and that builds value for its shareholders.”
Consistent with the Company’s commitment to strong corporate
governance, the Anika Board is underway in identifying an
additional director who will be joining the Board in the coming
months.
Dr. Blanchard currently serves as President and CEO of Keratin
Biosciences, Inc., a venture-backed biotech company developing
regenerative medicine and drug delivery therapies based on a
purified human-derived keratin technology platform. She also serves
as a director of SeaSpine Holdings Corporation, CeramTec GMBH,
Elute, and Bio2 Technologies, is a member of the National Academy
of Engineering, and advises a number of venture and private equity
clients.
Previously, she served in a number of leadership roles,
including Sr. Vice President and Chief Scientific Officer and GM,
Biologics, at Zimmer, Inc., a worldwide healthcare leader in the
design, development, manufacture and marketing of orthopedic
implants.
Dr. Blanchard holds 32 patents, many of which are used in
commercial applications, and has over 50 peer-reviewed
publications. She holds a Bachelor of Science with Honors in
Ceramic Engineering from Alfred University, and a Master of Science
and Ph.D. in Materials Science and Engineering, both from the
University of Texas at Austin.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA) technology.
Anika's orthopedic medicine portfolio includes ORTHOVISC®,
MONOVISC®, and CINGAL®, which alleviate pain and restore joint
function by replenishing depleted HA, and HYALOFAST, a solid
HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit
www.anikatherapeutics.com.
Forward-Looking StatementsThe statements made in the last
sentence of the third paragraph and the fifth paragraph of this
press release, which are not statements of historical fact, are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
include, but are not limited to, those relating to the Company’s
future revenue expectations and the composition of the Company’s
Board of Directors. These statements are based upon the current
beliefs and expectations of the Company’s management and are
subject to significant risks, uncertainties, and other factors,
including the availability of suitable director candidates. The
Company’s actual results could differ materially from any
anticipated future results, performance, or achievements described
in the forward-looking statements as a result of a number of
factors including, but not limited to, (i) the Company’s ability to
successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company’s ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company’s research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company’s clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company’s ability to successfully
commercialize its products, in the U.S. and abroad; (ix) the
Company’s ability to provide an adequate and timely supply of its
products to its customers; and (x) the Company’s ability to achieve
its growth targets. Additional factors and risks are described in
the Company’s periodic reports filed with the Securities and
Exchange Commission, and they are available on the SEC’s website at
www.sec.gov. Forward-looking statements are made based on
information available to the Company on the date of this press
release, and the Company assumes no obligation to update the
information contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180905005846/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerorFor Media Inquiries:Pure
Communications, Inc.Sonal Vasudev,
917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024